Running time: 2010-2014
Funding agency: Innovative Medicines Initiative (IMI)
Project website: http://www.ubiopred.european-lung-foundation.org/
Group researchers: Scott Chih-Hsi Kuo


U-BIOPRED (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes) is a research project to understand more about severe asthma that involves scientists from universities, research institutes, the pharmaceutical industry and small companies. It is funded by a programme set up in 2008 by both the European Commission and the European Federation of Pharmaceutical Industries and Associations called the Innovative Medicines Initiative (IMI).

The IMI aims to bring together industrial partners and university researchers, in an attempt to reduce barriers or bottlenecks that slow down the development of new medicines. It is also one of the first occasions that so many pharmaceutical companies are working together on the same project as partners and not as competitors. The overall aim of U-BIOPRED is to better understand the different types of severe asthma with the hope that this understanding will consider individual characteristics and make it easier to develop new medicines.

The Discovery Sciences Group has been responsible for building and hosting a translational medicine research informatics platform to execute over the IC Cloud and further developed it into a fully functional knowledge management system.